Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Future therapies for obesity

Open access

Abstract

Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7861/clinmed.2023-0144

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 2

  1. 2022, Diabetologia, 65, 1
  2. 53 Amgen,. Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022. www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022 [Accessed 25 May 2023].

Cited by

See all 46

Metadata

Authors
Melson, E., Miras, A. D., & Papamargaritis, D.
Affiliations
  • University of Leicester (GB)
  • University of Ulster (GB)
Venue
Clinical Medicine
Publisher
Elsevier BV
Published
2023-07
Volume
23
Issue
4
Pages
337-346
ISSN
1470-2118 (ISSN-L)
OpenAlex
W4385431101
Cited by
46
References
61
Citations by year
2026: 14 · 2025: 16 · 2024: 13 · 2023: 3
FWCI
7.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Ulster University Research Portal (Ulster University) (publishedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institute for Health and Care Research (ACF-2022-11-007)
  • NIHR Leicester Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity, obesity pharmacotherapy, bariatric surgery, gastrointestinal hormones, GLP-1 receptor agonists, GIP receptor agonist, tirzepatide, weight loss, type 2 diabetes, glucagon, amylin
MeSH terms
Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Humans, Obesity, Weight Loss, Bariatric Surgery, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Future therapies for obesity. https://app.cochat.ai/papers/10.7861/clinmed.2023-0144
The paper
Melson, E., Miras, A. D., & Papamargaritis, D. (2023). Future therapies for obesity. Clinical Medicine. https://doi.org/10.7861/clinmed.2023-0144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.